Skip to main content
. Author manuscript; available in PMC: 2009 Jul 28.
Published in final edited form as: Vaccine. 2008 Jun 2;26(32):4057–4061. doi: 10.1016/j.vaccine.2008.05.024

Table 2.

Co-primary immunogenicity endpoint* results by presentation, lot, placebo and for all active vaccine formulations

Multi-dose Vial (Thimerosal Containing)
Influenza Strain Immunogenicity evaluation Lot 1 N=270n (%) Lot 2 N=275 n (%) Lot 3 N=269 n (%) Prefilled Syringe (Thimerosal-free) N= 263 n (%) All active vaccines N=1077 n (%) Placebo N=264 n (%)
H1N1: A/Caledonia/20/99 Seroconversion or Significant Increase in Titer 131
(48.5%)		 133
(48.4%)		 132
(49.1%)		 128
(48.7%)		 524
(48.7%)		 6
(2.3%)
Seroprotection 261
(96.7%)		 270
(98.2%)		 262
(97.4%)		 260
(98.9%)		 1053
(97.8%)		 197
(74.6%)
H3N2:A/New York/55/2004 Seroconversion or Significant Increase in Titer 187
(69.3%)		 196
(71.3%)		 203
(75.5%)		 184
(70%)		 770
(71.5%)		 0
(0%)
Seroprotection 270
(100.0%)		 274
(99.6%)		 269
(100.0%)		 263
(100.0%)		 1076
(99.9%)		 190
(72.0)
B Strain: B/Malaysia/2506/2004 Seroconversion or Significant Increase in Titer 194
(71.9%)		 187
(68.0%)		 186
(69.1%)		 184
(70.0%)		 751
(69.7%)		 1
(0.4%)
Seroprotection 258
(95.6%)		 258
(93.8%)		 250
(92.9%)		 249
(94.7%)		 1015
(94.2%)		 124
(47.0%)
*

Seroconversion or Significant Increase in titer is defined as pre-vaccination HI < 10 increased to HI ≥ 40 postvaccination or fourfold rise in prevaccination titer. Seroprotection is defined as HI ≥ 40.